BioMedNewsBreaks

ThursdayApr 01, 2021 10:33 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Reports Update in Shareholder Letter

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has provided a corporate update in a shareholder letter from LexaGene CEO and founder Dr. Jack Regan. In the letter, Regan reported that the company had crossed a major milestone by securing a sales contract in both the drug and vaccine manufacturing market and in the veterinary medicine space; both sales were the result of successful technology demonstrations, the letter noted. The company has also focused on ensuring consistency in microfluidic operations across MiQLab(TM) systems, Regan observed, noting that expectations have now been…

Continue Reading

TuesdayMar 30, 2021 2:33 pm

BioMedNewsBreaks – BioSig Technologies Inc. (NASDAQ: BSGM) Awarded U.S. Patent Claims for PURE EP(TM) Noise-Filtering Technology

BioSig Technologies (NASDAQ: BSGM), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent covering its PURE EP(TM) noise-filtering technology. According to the update, the recently allowed patent application number 17/082,564, entitled, “SYSTEMS AND METHODS FOR PERFORMING ELECTROPHYSIOLOGY (‘EP’) SIGNAL PROCESSING " was filed on October 28, 2020. "We are pleased to announce this newest patent allowance, which demonstrates the clinical significance of our PURE EP(TM) System in filtering noise from complex cardiac…

Continue Reading

TuesdayMar 30, 2021 12:25 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Preclinical Data Highlighting Potential for TUSC2 Immunogene Therapy to Be Featured at AACR 21

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell lung cancer (“NSCLC”), will be featured in two presentations at the upcoming annual meeting of the American Association for Cancer Research (“AACR 21”). The event is slated to take place virtually from April 9-14, 2021. “We look forward to the presentation of these data that…

Continue Reading

TuesdayMar 30, 2021 11:39 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils New MyoCorrect Orofacial Myofunctional Therapy Service

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has announced a new service called MyoCorrect. The exclusive training provides therapists with access to orofacial myofunctional therapy (“OMT”) via telemedicine technology using the company’s Vivos System. Vivos anticipates this new service will provide increased revenue through With this new training, Vivos expects to see additional revenue through increased cases and fees. The company expects its MyoCorrect service will become an effective treatment of OSA, thereby giving Vivos an additional competitive advantage in the OSA treatment…

Continue Reading

TuesdayMar 30, 2021 11:04 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Multi-Omic Approach to New Drug Discovery

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. Predictive Oncology is confident that a multi-omic approach offers a much greater ability for success. The company is a leader in this area where few comprehensive, multi-omic datasets exist, especially in cancer, and such data is difficult to quickly access, as well as costly and…

Continue Reading

MondayMar 29, 2021 3:29 pm

BioMedNewsBreaks – Healthtech Solutions Inc.’s (HLTT) Medi-Scan Featured in BioWorld(TM) Article

Healthtech Solutions’ (OTC: HLTT) subsidiary, Medi-Scan Inc., was featured in a recent BioWorld(TM) article titled, “Medi-Scan’s digital tool converts ultrasound images to 3D at the point of care.” The piece discusses Medi-Scan’s cloud-based software that has the capability to rapidly (in less than two minutes) convert the data on ultrasound analog 2D grayscale images into a digital 3D high-definition (“HD”) format. The company’s efforts currently focus on the heart and lungs, as it aims to provide quick, point-of-service evaluation and triaging of patients with heart disease and other conditions, including those suffering from COVID-19. Medi-Scan’s machine learning-based solution provides clinicians…

Continue Reading

MondayMar 29, 2021 1:35 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Featured in Latest Episode of Bell2Bell Podcast

United Medical Equipment (“UME,” “UMEBSNI”) was featured in the The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. UME’s President, Jason Pratt, and VP of Sales, Brian Gartland, joined the latest episode to discuss United Medical Equipment’s trusted-provider business model. “Every day, 10,000 people turn 65 in the United States. Having a home health background, I saw the need to have trusted resources for seniors and their families,” Pratt said in the interview. “A lot of home health care companies are only worried about their census, not about providing good…

Continue Reading

MondayMar 29, 2021 1:10 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Cost-Effective, Compact Solutions to Emergency Medicine

Brain Scientific (OTCQB: BRSF), with its low-cost, portable, wireless and easy-to-use electroencephalogram (“EEG”) devices, the NeuroCap(TM) and NeuroEEG(TM), has overcome the barriers preventing the use of EEGs in emergency settings. This means that patients and emergency departments can more readily realize numerous EEG benefits. An EEG can make the distinction between dementia and delirium, adequately determine the severity of a mild traumatic brain injury (“mTBI”), as well as identify nontraumatic causes of neurologic dysfunction such as syncope and vertigo. In contrast, head CTs or MRIs are not equipped to effectively perform any of these tasks, yet they are widely used.…

Continue Reading

MondayMar 29, 2021 11:53 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in NetworkNewsAudio Broadcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, this morning announced that it was featured in a NetworkNewsAudio production highlighting the company’s recent news that it has received European approval for its SARS-CoV-2 (COVID-19) RT-PCR test system (Covid-ID Lab). “Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” XPhyto CEO and Director Hugh Rogers…

Continue Reading

FridayMar 26, 2021 2:01 pm

BioMedNewsBreaks – RYAH Group Inc. Holds Key Distinction in Telehealth Era

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, appears ready to respond to strict data security requirements. This is an important distinction in an era where the use of telehealth solutions is exploding while securing the integrity of patient information remains critical. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) is U.S. legislation surrounding requirements for medical providers to integrate privacy and security provisions to safeguard their patient’s medical data. Although HIPAA guidelines are temporarily relaxed during the pandemic, this flexibility is not likely to remain and it is. Therefore, it is…

Continue Reading